Statement of Ownership (sc 13g)
April 07 2017 - 4:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
"Washington, D.C. 20549"
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
IGENE BIOTECHNOLOGY INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
451695100
(CUSIP Number)
7-Apr-17
(Date of
Event which Requires Filing of this Statement)
Checktheappropriatebox to designate the rule
pursuant to which this Schedule is filed:
[x_] Rule 13d-1(b)
[_] Rule 13d-1(c)
[_] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for
a reporting persons initial
filing on this form with respect to the subject class of
"securities, and for any subsequent "
amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover
page shall not be deemed to be filed
for the purpose of Section 18 of the Securities Exchange
Act of 1934 (Act) or otherwise subject to
the liabilities of that section of the Act but shall be
"subject to all other provisions of the Act (however, see the Notes)."
SCHEDULE 13G
CUSIP No.
451695100
1
Names of Reporting Persons
CANACCORD GENUITY
2
Check the appropriate box if a member of a Group (see instructions)
(a)[ ]
(b)[ ]
3
Sec Use Only
4
Citizenship or Place of Organization
"535 MADISON AVENUE, "
"NEW YORK, NY 10022"
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0
6
Shared Voting Power
0
7
Sole Dispositive Power
"52,681,260"
8
Shared Dispositive Power
0
9
Aggregate Amount Beneficially Owned by Each Reporting Person
100%
10
Check box if the aggregate amount in row (9)
excludes certain shares (See Instructions)
[ ]
11
Percent of class represented by amount in row (9)
3%
12
Type of Reporting Person (See Instructions)
BD
Item 1.
(a) Name of Issuer: IGENE BIOTECHNOLOGY
(b) Address of Issuers Principal Executive Offices:
9110 RED BRANCH ROAD
"COLUMBIA, MD 21045-2024"
Item 2.
(a) Name of Person Filing: Canaccord Genuity
"(b) Address of Principal Business Office or, if None, Residence:"
"535 MADISON AVENUE, NY NY 10022"
(c) Citizenship: US
(d) Title and Class of Securities: COMMON STOCK
(e) CUSIP No.: 451695100
Item 3. If this statement is filed pursuant to 240.13d-1(b)
"or 240.13d-2(b) or (c), check whether the person filing is a:"
(a) [X_] Broker or dealer registered under Section 15 of the Act;
(b) [_] Bank as defined in Section 3(a)(6) of the Act;
(c) [_] Insurance company as defined in Section 3(a)(19) of the Act;
(d) [_] Investment company registered under Section 8 of the
Investment Company Act of 1940;
(e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance
with Rule 13d-1(b)(1)(ii)(G);
(h) [_] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [_] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act of 1940;
(j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
(k) [_] "Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If "
filing as a non-U.S. institution in accordance with
"Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____"
Item 4. Ownership
(a) Amount Beneficially Owned: "$15,804.37 "
(b) Percent of Class: 3.37
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
(ii) Shared power to vote or to direct the vote:
"(iii) Sole power to dispose or to direct the disposition of: 280,021,302"
(iv) Shared power to dispose or to direct the disposition of:
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more
"than five percent of the class of securities, check the following [ ]."
Item 6. Ownership of more than Five Percent on Behalf of Another Person.
Item 7. Identification and classification of the subsidiary which acquired
the security being reported on by the parent holding company
or control person.
Item 8. Identification and classification of members of the group.
Item 9. Notice of Dissolution of Group.
Item 10. Certifications.
SIGNATURE
"After reasonable inquiry and to the best of my knowledge and belief,"
" I certify that the information set forth in this statement is true, "
complete and correct.
"Dated:April 07, 2017"
/s/ Signature
"Name/Title: Michael Norton, Complaince Associate" Michael Norton
The original statement shall be signed by each person on whose behalf
the statement is filed or his authorized representative. If the statement
is signed on behalf of a person by his authorized representative (other
" than an executive officer or general partner of this filing person), "
evidence of the representative's authority to sign on behalf of such
"person shall be filed with the statement, provided, however, that a power"
of attorney for this purpose which is already on file with the Commission
may be incorporated by reference. The name and any title of each person
who signs the statement shall be typed or printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).
Page 5 of 5
1297544.3
|
IGENE Biotechnology (CE) (USOTC:IGNE)
Historical Stock Chart
From Jul 2024 to Aug 2024
IGENE Biotechnology (CE) (USOTC:IGNE)
Historical Stock Chart
From Aug 2023 to Aug 2024